Big Pharma GCCs In India: From Back-Office Ops To Innovation Catalysts

India is seeing a flurry of activity with big pharma either establishing or expanding their global capability centers in the country. Can these hubs reshape the contours of industry’s operating model across a range of functions and perhaps spawn a pipeline of new leaders along the way?

Pharma bets big on GCCs in India

“The things I hear about when I walk around the floors in Hyderabad are the things that are on my desk as CEO of Novartis,” said Vas Narasimhan at a press meet last year, referring to the increasingly pivotal contribution of the company’s Global Capability Center (GCC) in India to the Swiss group’s global operations.

More from In Vivo

HealthTech Innovation Versus Clinician And System Awareness

 
• By 

Bringing AI and digital healthtech innovation to patients works most efficiently via a three-way partnership in which clinicians and cloud services have equal weighting with a powerhouse innovator, Royal Philips told In Vivo during ECR 2025.

In Conversation: Sketching The Future Of Biotech Investment With Lilly Ventures

 
• By 

Laura Lane, European head of Lilly Ventures, talked to In Vivo at the recent Bio-Europe meeting in a fireside chat about how strategic investments are shaping the future of biotech, Lilly's approach to early-stage innovation, and the evolving European investment landscape.

Laying The Foundation And Overcoming Prerequisites To Establish AI Within Health Care

 
• By 

As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.

Regenxbio’s Triple Threat: Partnered Programs, DMD Progress And In-House Manufacturing

 
• By 

Regenxbio is riding a wave these days, with all three of its clinical-stage programs set to reach critical milestones this year and recent positive news on its DMD gene therapy, just as Sarepta suffered a setback with a death related to its DMD treatment. In Vivo spoke with CEO Curran Simpson about the company’s plans and strategic decisions.

More from Innovation

BPGbio: Fusing Patient-Driven Innovation With Causal AI

 
• By 

Biotech BPGbio applies causal AI to generate insights from samples from what the CEO says is one of the world's largest biobanks. With several promising late-stage programs, its platform seems to be yielding fruit.

20 Voices: What Does 2025 Hold For Biopharma?

 

Twenty executives in the biopharma industry outline their expectations for key trends and developments this year. A selection of commentary from a broad industry survey by Scrip.

Biotech Aims For NET Gains By Targeting Neutrophil Extracellular Traps

 
• By 

Neutrophil Extracellular Traps are a double-edged sword in the immune system, capable of both defending against pathogens and driving inflammatory diseases. Their complex role in health and disease is being approached by innovative researchers and biotechs, who are working to harness their power while mitigating their harmful effects.